JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Jazz Pharmaceuticals plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $4.38B | $4.21B | $4.02B | $3.91B | $3.84B | $3.82B | $3.82B | $3.76B | $3.71B | $3.69B | $3.74B | $3.74B | 95.2% | +14.0% |
| Xywav | $1.78B | $1.72B | $1.66B | $1.59B | $1.55B | $1.50B | $1.47B | $1.41B | $1.35B | $1.31B | $1.27B | $1.22B | 38.6% | +14.6% |
| Epidiolex/Epidyolex | $1.13B | $1.09B | $1.06B | $1.05B | $996.01M | $991.41M | $972.42M | $938.00M | $900.15M | $855.28M | $845.47M | $811.84M | 24.6% | +13.6% |
| Rylaze/Enrylaze | $411.23M | $412.43M | $402.92M | $396.26M | $395.17M | $402.30M | $410.85M | $411.11M | $417.19M | $411.05M | $394.23M | – | 8.9% | +4.1% |
| Zepzelca | $376.54M | $345.24M | $307.31M | $295.12M | $301.67M | $308.22M | $320.32M | $316.00M | $308.15M | $297.45M | $289.53M | $287.49M | 8.2% | +24.8% |
| Royalties and contract revenues | $222.97M | $230.87M | $245.74M | $243.16M | $246.72M | $246.31M | $247.79M | $229.42M | $197.90M | $148.55M | $97.26M | $57.26M | 4.8% | -9.6% |
| Defitelio/defibrotide | $220.02M | $206.12M | $199.39M | $198.20M | $212.27M | $209.59M | $216.57M | $210.00M | $191.91M | $192.60M | $184.00M | $173.57M | 4.8% | +3.7% |
| High-sodium oxybate AG royalty revenue | $187.14M | $199.04M | $211.73M | $211.25M | $216.46M | $216.53M | $217.58M | $201.66M | $172.42M | $123.77M | $75.92M | $36.53M | 4.1% | -13.5% |
| Modeyso | $137.17M | $89.47M | $48.04M | $11.53M | $500.00K | – | $0 | – | – | – | – | – | 3.0% | +27334.6% |
| Xyrem | $135.14M | $140.04M | $146.03M | $157.55M | $180.00M | $206.78M | $233.82M | $291.25M | $358.24M | $455.83M | $569.73M | $710.51M | 2.9% | -24.9% |
| Vyxeos | $130.31M | $143.81M | $146.71M | $165.23M | $161.96M | $160.07M | $162.60M | $156.26M | $151.77M | $142.82M | $147.50M | $130.85M | 2.8% | -19.5% |
| Ziihera | $45.54M | $36.14M | $24.81M | $17.36M | $9.05M | $3.05M | $1.05M | – | – | – | – | – | 1.0% | +403.2% |
| Other | $8.15M | $16.65M | $14.17M | $23.92M | $24.00M | $18.20M | $11.47M | $12.59M | $13.26M | $13.98M | $13.85M | $12.83M | 0.2% | -66.0% |
| Sunosi | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Sativex | – | – | $16.28M | $19.95M | $19.78M | $21.55M | $18.88M | $18.84M | $18.88M | $15.31M | $19.67M | $19.25M | – | – |
| Rylaze | – | – | – | – | – | – | – | – | – | – | $394.23M | $373.45M | – | – |
| Total Neuroscience | – | – | $2.88B | $2.82B | $2.75B | $2.72B | $2.70B | $2.66B | $2.63B | $2.64B | $2.71B | $2.76B | – | – |
| Total Oncology | – | – | $1.13B | $1.08B | $1.08B | $1.08B | $1.11B | $1.09B | $1.07B | $1.04B | $1.02B | $965.36M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.13B | $3.99B | $3.83B | $3.73B | $3.66B | $3.65B | $3.66B | $3.60B | $3.53B | $3.49B | $3.49B | $3.48B | 89.9% | +12.9% |
| Europe | $365.12M | $350.42M | $341.12M | $334.59M | $325.50M | $324.96M | $312.71M | $305.88M | $297.53M | $274.70M | $269.24M | $252.01M | 7.9% | +12.2% |
| All other | $101.61M | $95.31M | $94.87M | $94.89M | $99.65M | $90.02M | $96.14M | $89.78M | $84.39M | $80.60M | $74.98M | $59.36M | 2.2% | +2.0% |
From the segment and revenue-disaggregation notes of Jazz Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.